{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-008249","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.820340+00:00","generated_at":"2026-05-24T12:51:28.238847+00:00","sec_items":["2.02","9.01","7.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CervoMed reports Q4/FY2024 results; positive Phase 2b extension data for neflamapimod in DLB","bullets":["Cash $38.9M at Dec 31, 2024 (up from $7.8M); funded into mid-2026.","Net loss $16.3M for FY2024 vs $2.2M in 2023 (2023 included noncash gain).","Positive 16-week extension results: improvement on CDR-SB (p<0.001 vs old capsules; p=0.003 vs placebo).","Plan to initiate Phase 3 trial in mid-2026 after regulatory meetings.","Added senior VPs Claudia Ordonez (Medical Science) and Mark De Rosch (Regulatory)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-008249","json":"https://secwatch.observer/filing/0001437749-25-008249.json","markdown":"https://secwatch.observer/filing/0001437749-25-008249.md","text":"https://secwatch.observer/filing/0001437749-25-008249.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925008249/0001437749-25-008249-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925008249/crvo20250318_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T12:51:28.238847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}